mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2024-5-103-106mrj-1646Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSПрименение ритуксимаба при сочетании иммуновоспалительных ревматических заболеваний с болезнью Грейвса (аутоиммунным полигландулярным синдромом взрослых): описание случаев и обзор литературыUse of rituximab in the of immunoinflammatory rheumatic diseases combined with Graves' disease (autoimmune polyglandular syndrome in adults): case report and literature reviewhttps://orcid.org/0000-0002-5290-156XПаневинТ. С.PanevinT. S.

Тарас Сергеевич Паневин

115522, Москва, Каширское шоссе, 34А; 680000, Хабаровск, ул. Муравьева-Амурского, 35

Taras Sergeyevich Panevin

34A, Kashirskoe Shosse, Moscow 115522; 35, Muravyov-Amurskogo Street, Khabarovsk 680000

tarasel@list.ruhttps://orcid.org/0000-0002-4579-2836ЗоткинЕ. Г.ZotkinE. G.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ВО «Дальневосточный государственный медицинский университет» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Far Eastern State Medical University, Ministry of Health of RussiaRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202420102024185103106Copyright © Паневин Т.С., Зоткин Е.Г., 20242024Паневин Т.С., Зоткин Е.Г.Panevin T.S., Zotkin E.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1646

Ритуксимаб (РТМ) – химерное (мышиное и человеческое) моноклональное антитело к B-лимфоцитам (CD20). РТМ широко применяется в гематологии при лимфопролиферативных заболеваниях, а в ревматологии – при ревматоидном артрите, болезни Шегрена, некоторых видах васкулитов и системных заболеваний соединительной ткани. Введение РТМ сопровождается B-клеточной деплецией за счет регулирования апоптоза и цитотоксического эффекта, опосредованного комплимент-зависимыми и антителозависимыми механизмами. Учитывая патогенез аутоиммунного повреждения при болезни Грейвса (БГ), аутоимммунном заболевании щитовидной железы, сопровождающемся тиреотоксикозом, применение РТМ может быть эффективным при данной патологии. Представлено описание 3 больных с сочетанием диффузного токсического зоба и ревматической патологии, по поводу которой проводилась терапия РТМ, при этом наблюдались разные исходы БГ.

Rituximab (RTM) is a chimeric (murine and human) monoclonal antibody against B-lymphocytes (CD20). RTM is widely used in hematology for lymphoproliferative diseases and in rheumatology for rheumatoid arthritis, Sjögren's disease, some types of vasculitis and systemic connective tissue diseases. The administration of RTM is associated with a depletion of B-cells mediated by the regulation of apoptosis and cytotoxic effects via complement-dependent and antibody-dependent mechanisms. Considering the pathogenesis of autoimmune damage in Graves' disease (GD), an autoimmune thyroid disease associated with thyrotoxicosis, the use of RTM could be effective in this pathology. We present three patients with a combination of diffuse toxic goiter and rheumatic pathology treated with RTM; different outcomes of GD were observed.

ритуксимабболезнь Грейвсадиффузный токсический зобсистемная красная волчанкасистемная склеродермиямикроскопический полиангиитrituximabGraves' diseasediffuse toxic goitersystemic lupus erythematosussystemic sclerodermamicroscopic polyangiitisИсследование не имело спонсорской поддержки.The investigation has not been sponsored.ReferencesТрошина ЕА, Свириденко НЮ, Ванушко ВЭ и др. Федеральные клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечению токсического зоба. Клиническая и экспериментальная тиреоидология. 2014; 10(3):8-19.Troshina EA, Sviridenko NYu, Vanushko VE, et al. Russian Association of Endocrinologists clinical practice guidelines for thyrotoxicosis diagnosis and treatment. Klinicheskaya i eksperimental'naya tireoidologiya. 2014;10(3): 8-19. (In Russ.)Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006 May;6(5 Pt 1): 859-66. doi: 10.1111/j.1600-6143.2006.01288.x.Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006 May;6(5 Pt 1): 859-66. doi: 10.1111/j.1600-6143.2006.01288.x.Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 "what do B-cells do?". Clin Immunol. 2005 Dec;117(3):207-13. doi: 10.1016/j.clim.2005.08.006. Epub 2005 Sep 19.Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 "what do B-cells do?". Clin Immunol. 2005 Dec;117(3):207-13. doi: 10.1016/j.clim.2005.08.006. Epub 2005 Sep 19.Паневин ТС, Зоткин ЕГ, Трошина ЕА, Лукина ГВ. Ритуксимаб в лечении болезни Грейвса и эндокринной офтальмопатии. Возможности и ограничения. Научнопрактическая ревматология. 2023;61(5): 545-553.Panevin TS, Zotkin EG, Troshina EA, Lukina GV. Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitations. Nauchno-Prakticheskaya Revmatologia. 2023;61(5):545-553. (In Russ.)Hasselbalch HC. B-cell depletion with rituximab – a targeted therapy for Graves' disease and autoimmune thyroiditis. Immunol Lett. 2003 Jul 3;88(1):85-6. doi: 10.1016/s0165-2478(03)00032-4.Hasselbalch HC. B-cell depletion with rituximab – a targeted therapy for Graves' disease and autoimmune thyroiditis. Immunol Lett. 2003 Jul 3;88(1):85-6. doi: 10.1016/s0165-2478(03)00032-4.Паневин ТС, Зоткин ЕГ, Трошина ЕА. Аутоиммунный полиэндокринный синдром взрослых. Фокус на ревматологические аспекты проблемы. Терапевтический архив. 2023;95(10):881-887.Panevin TS, Zotkin EG, Troshina EA. Autoimmune polyendocrine syndrome in adults. Focus on rheumatological aspects of the problem: A review. Terapevticheskii Arkhiv. 2023; 95(10):881-887. (In Russ.)Ferrari SM, Fallahi P, Ruffilli I, et al. The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series. Autoimmun Rev. 2019 Mar;18(3):287-292. doi: 10.1016/j.autrev.2018.10.001. Epub 2019 Jan 11.Ferrari SM, Fallahi P, Ruffilli I, et al. The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series. Autoimmun Rev. 2019 Mar;18(3):287-292. doi: 10.1016/j.autrev.2018.10.001. Epub 2019 Jan 11.El Fassi D, Nielsen CH, Hasselbalch HC, Hegedьs L. The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol. 2006 May; 154(5):623-32. doi: 10.1530/eje.1.02140.El Fassi D, Nielsen CH, Hasselbalch HC, Hegedьs L. The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol. 2006 May; 154(5):623-32. doi: 10.1530/eje.1.02140.El Fassi D, Nielsen CH, Bonnema SJ, et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab. 2007 May;92(5):1769-72. doi: 10.1210/jc.2006-2388. Epub 2007 Feb 6.El Fassi D, Nielsen CH, Bonnema SJ, et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab. 2007 May;92(5):1769-72. doi: 10.1210/jc.2006-2388. Epub 2007 Feb 6.Heemstra KA, Toes RE, Sepers J, et al. Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol. 2008 Nov; 159(5):609-15. doi: 10.1530/EJE-08-0084. Epub 2008 Jul 15.Heemstra KA, Toes RE, Sepers J, et al. Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol. 2008 Nov; 159(5):609-15. doi: 10.1530/EJE-08-0084. Epub 2008 Jul 15.Cheetham TD, Cole M, Abinun M, et al. Adjuvant Rituximab-Exploratory Trial in Young People With Graves Disease. J Clin Endocrinol Metab. 2022 Feb 17;107(3):743-754. doi: 10.1210/clinem/dgab763.Cheetham TD, Cole M, Abinun M, et al. Adjuvant Rituximab-Exploratory Trial in Young People With Graves Disease. J Clin Endocrinol Metab. 2022 Feb 17;107(3):743-754. doi: 10.1210/clinem/dgab763.Jang SY, Shin DY, Lee EJ, et al. Correlation between TSH receptor antibody assays and clinical manifestations of Graves' orbitopathy. Yonsei Med J. 2013 Jul;54(4):1033-9. doi: 10.3349/ymj.2013.54.4.1033.Jang SY, Shin DY, Lee EJ, et al. Correlation between TSH receptor antibody assays and clinical manifestations of Graves' orbitopathy. Yonsei Med J. 2013 Jul;54(4):1033-9. doi: 10.3349/ymj.2013.54.4.1033.Karasek D, Cibickova L, Karhanova M, et al. Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very lowdose rituximab. Endokrynol Pol. 2017;68(5): 498-504. doi: 10.5603/EP.a2017.0040. Epub 2017 Jun 29.Karasek D, Cibickova L, Karhanova M, et al. Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very lowdose rituximab. Endokrynol Pol. 2017;68(5): 498-504. doi: 10.5603/EP.a2017.0040. Epub 2017 Jun 29.Supronik J, Szelachowska M, Kretowski A, Siewko K. Rituximab in the treatment of Graves' orbitopathy: latest updates and perspectives. Endocr Connect. 2022 Nov 25; 11(12):e220303. doi: 10.1530/EC-22-0303. Print 2022 Dec 1.Supronik J, Szelachowska M, Kretowski A, Siewko K. Rituximab in the treatment of Graves' orbitopathy: latest updates and perspectives. Endocr Connect. 2022 Nov 25; 11(12):e220303. doi: 10.1530/EC-22-0303. Print 2022 Dec 1.El Fassi D, Banga JP, Gilbert JA, et al. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol. 2009 Mar;130(3):252-8. doi: 10.1016/j.clim.2008.09.007. Epub 2008 Oct 28.El Fassi D, Banga JP, Gilbert JA, et al. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol. 2009 Mar;130(3):252-8. doi: 10.1016/j.clim.2008.09.007. Epub 2008 Oct 28.Vannucchi G, Campi I, Bonomi M, et al. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol. 2010 Sep;161(3):436-43. doi: 10.1111/j.1365-2249.2010.04191.x.Vannucchi G, Campi I, Bonomi M, et al. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol. 2010 Sep;161(3):436-43. doi: 10.1111/j.1365-2249.2010.04191.x.Chen J, Chen G, Sun H. Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis. Hormones (Athens). 2021 Jun;20(2):279-286. doi: 10.1007/s42000-021-00282-6. Epub 2021 Mar 30.Chen J, Chen G, Sun H. Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis. Hormones (Athens). 2021 Jun;20(2):279-286. doi: 10.1007/s42000-021-00282-6. Epub 2021 Mar 30.

The authors declare that there are no conflicts of interest present.